Medpace Holdings Inc
MEDP: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $442.00 | Vncnvt | Zshkbhc |
Narrow-Moat Medpace Benefits From Healthy Clinical Trial Outsourcing Demand; Positive Outlook
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
Business Strategy and Outlook
Medpace is a global, late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. The company was founded over 30 years ago in Cincinnati, Ohio. Its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia.